- cafead May 27, 2020 at 10:52: AM
via Last month, rumors out of Bloomberg whispered that Gilead Sciences, more known for its COVID-19 work these days, was gearing up for a major stake in immuno-oncology player Arcus.
Today, we learned those rumors were true, and there’s some big bucks action behind it: Gilead is paying $175 million upfront with a $200 million equity investment weighted in.
article source
Today, we learned those rumors were true, and there’s some big bucks action behind it: Gilead is paying $175 million upfront with a $200 million equity investment weighted in.
article source